Affiliation : IU-Indianapolis
Andi Masters, M.S.
Scientific Director: Zeruesenay Desta, Ph.D.
Medical Director: Jamie L. Renbarger, M.D., M.S.
Established in 2004 in response to a growing need for pharmacokinetic (PK) analysis and modelling, the Clinical Pharmacology Analytical Core (CPAC) assists investigators by providing detailed information on drug and metabolite concentrations in plasma and tissues, protein binding of drugs and proper formulations to use with drug studies. Additional services include preliminary determination of drug stability, drug metabolism and metabolite screening. The CPAC contains the necessary laboratory equipment, HPLC-MS/MS instruments (4 HPLC-MS/MS’s and 1 HPLC-UV), and personnel to accomplish these tasks. The process of rational drug design is built upon a strong foundation of biology, chemistry, in vivo pharmacology, and PK. Relevant PK and metabolism studies should be conducted in small animal models or in vitro systems before initial drug administration to humans. These studies allow for the iterative process of implementing structural changes in a drug molecule to optimize the activity of the drug and its PK properties prior to moving to the more regulated and expensive clinical phase of drug development. PK plays an important role in the determination of drug action in preclinical and clinical studies. The drug discovery process should provide a delicate balance between the chemistry, pharmacology, and PK of the drug. To coordinate these efforts, CPAC works closely with In Vivo Therapeutics (IVTC), Chemical Genomics, Center for Computational Biology and Bioinformatics, and other CTSI shared resources. CPAC’s state-of-the-art technology and expertise supports research and development of safe and more efficacious drug treatment for investigators.
Email This Core